Breast Cancer Vaccine STEMVAC: What Are Trials Testing?

How could a DNA vaccine help treat breast cancer?

An August interview with Wisconsin oncologist Vincent Ma highlighted breast cancer DNA-vaccine research alongside widely discussed melanoma advances. This provides a separate question for patients and researchers: can vaccination help the immune system recognize breast cancer that survives treatment? Wisconsin Medicine has described participation in a phase 2 study involving people previously treated for triple-negative breast cancer. [WPR interview](https://www.wpr.org/news/wisconsin-doctor-responds-breakthrough-trial-new-cancer-vaccine), [Wisconsin Medicine research overview](https://www.wiscmedicine.org/impact/eva-vivian).

STEMVAC uses a DNA plasmid carrying instructions related to five cancer-associated antigens. Its intended effect is to stimulate immune cells against those targets. The broader rationale is explained by the National Cancer Institute: treatment vaccines can teach the immune system to recognize antigens found on cancer cells. Whether that recognition translates into lasting control of breast cancer requires clinical evidence. [NCI STEMVAC description](https://prevention.cancer.gov/clinical-trials/clinical-trials-search/nct05455658), [NCI cancer treatment vaccines](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/cancer-treatment-vaccines).

What is the STEMVAC trial after breast cancer treatment measuring?

The phase 2 study registered as NCT05455658 involves people with previously treated early-stage triple-negative breast cancer who are in remission. Its principal question is whether vaccination generates responses from antigen-specific immune cells known as type 1 helper T cells. The protocol includes an initial series of three monthly injections, subsequent boosters and longer-term follow-up. These are study procedures, not an established vaccination schedule for routine care. [NCI trial description](https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2021-07734).

The study also explores relapse-free survival using historical controls. That design matters when interpreting eventual findings: differences from patients treated in another period can reflect changes in care or patient characteristics. An immune response would show biological activity, but would not by itself establish that vaccination prevents recurrence. A convincing treatment claim requires evidence of patient benefit alongside acceptable harms.

Could STEMVAC also help people with metastatic breast cancer?

Trial NCT07078604 addresses cancer that has spread beyond the breast and nearby lymph nodes. Participants receive chemotherapy selected by their oncologist alongside experimental STEMVAC vaccination. The main objectives include safety and immune responses; additional outcomes include tumor response, progression-free survival and overall survival. The protocol also investigates changes in immune cells within tumors. These are planned measurements, not reported improvements. [NCI metastatic breast cancer trial](https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2025-04327).

This combination approach asks whether vaccination can add benefit to existing treatment. For patients, the practical distinction is between an investigational option and therapies supported for their particular disease setting. The National Cancer Institute describes chemotherapy, immunotherapy and targeted medicines among treatments for metastatic triple-negative breast cancer, with selection depending on individual features. Trial participation should be discussed in that context, including additional visits, research procedures and uncertain benefits. [NCI treatment guidance](https://www.cancer.gov/types/breast/treatment/triple-negative-breast-cancer).